Zealand Pharma A/S ADR (ZEAL)

NASDAQ
Currency in USD
17.59
0.00(0.00%)
Closed·
Showing Zealand Pharma ADR historical data. For real-time data please try another search
Day's Range
17.4718.07
52 wk Range
17.4718.07
Key Statistics
Edit
Prev. Close
17.59
Open
18.03
Day's Range
17.47-18.07
52 wk Range
17.47-18.07
Volume
-
Average Vol. (3m)
3.08K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Zealand Pharma A/S ADR News & Analysis

Show more

Zealand Pharma A/S ADR Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.

Industry
-
Sector
-
Employees
385

Zealand Pharma A/S ADR Earnings Call Summary for Q1/2025

  • Zealand Pharma reported Q1 2025 revenue of 8 million DKK, driven by Segalog license agreement with Novo Nordisk
  • Anticipates $1.4 billion upfront payment from Roche in Q2 2025, strengthening cash position to 18 billion DKK
  • Projecting net operating expenses of 2-2.5 billion DKK for 2025; confident in achieving profitability without additional capital raising
  • Strengthening obesity treatment pipeline with multiple trials; CEO expresses confidence in betralentide's potential
  • Analysts maintain strong buy consensus with price targets ranging from $110 to $169 per share
Last Updated: 05/08/2025, 09:21 AM
Read Full Transcript

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-4.75 / --
Revenue / Forecast
8.09M / --
EPS Revisions
Last 90 days

ZEAL Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.